Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population

135Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Whether a recent large decline in use of postmenopausal hormone therapy after the release of the Women's Health Initiative findings in July 2002 and/or a decline in screening mammography use is related to a recently reported decline in breast cancer incidence in the United States is controversial. We prospectively collected data from four screening mammography registries from January 1997 through December 2003 for 603411 screening mammography examinations performed on women aged 50-69 years. Of these women, 3238 were diagnosed with breast cancer within 12 months of a screening examination. We calculated quarterly rates of self-reported current postmenopausal hormone therapy use and of invasive breast cancer, ductal carcinoma in situ (DCIS), and estrogen receptor (ER)-positive invasive breast cancer adjusted for age, registry, and time between screening examinations. All statistical tests were two-sided. Between 2000 and 2002 and between 2002 and 2003, annual rates of postmenopausal hormone therapy use declined by 7% and 34%, respectively (Ptrend

Cite

CITATION STYLE

APA

Kerlikowske, K., Miglioretti, D. L., Buist, D. S. M., Walker, R., & Carney, P. A. (2007). Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. Journal of the National Cancer Institute, 99(17), 1335–1339. https://doi.org/10.1093/jnci/djm111

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free